Background. Knowledge of mortality in patients with Chronic Hepatitis C (CHC) with
A c c e p t e d M a n u s c r i p t 4 An estimated 5-20% of patients with chronic hepatitis c (CHC) will develop liver cirrhosis [1] . The prevalence of CHC in Denmark is estimated to be 0.38 -0.49% of whom only half are aware of their HCV status and even fewer attend specialized care [2] . Liver cirrhosis induced by CHC is a serious health issue with potential complications including decompensation or hepatocellular carcinoma (HCC) [3] [4] [5] and is associated with increased mortality [6] [7] [8] . Achieving Sustained Virologic Response 24 weeks after end of treatment (EOT) (SVR24) [9] in patients with severe fibrosis or cirrhosis is associated with reduced mortality [10] . Since risk factors associated with poor health outcomes are prevalent among patients who acquire CHC [11, 12] and cirrhosis per se is associated with poor outcomes regardless of etiology [6] , it is not surprising to find an increased mortality rate compared to the general population [5, 11] . CHC patients with and without cirrhosis share many of the same underlying behavioural risk factors, and CHC patients free of cirrhosis can serve as a comparison group to estimate mortality associated with cirrhosis.
Previous studies of mortality in patients with CHC-induced cirrhosis have been based on selected, relatively small cohorts in single or multi-centre studies [4, 5, 8] . To the best of our knowledge, no previous studies have included patients from all CHC-managing outpatient clinics in a country to estimate mortality in a large cohort of patients with CHC and liver cirrhosis and estimated the mortality associated with SVR24 in cirrhotic patients. Denmark provides an ideal setting to carry out large cohort studies due to a long tradition of registries with the possibility of inter-registry linkage [13] [14] [15] . The aims of this study were to estimate the all-cause mortality in CHC patients with cirrhosis and compare this to CHC patients without cirrhosis and to the general population. Furthermore we aimed to estimate mortality associated with SVR24 in patients with cirrhosis and compare this to the general population.
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METHODS
Study design
This observational cohort study is based on prospectively collected data from nationwide registries. The Danish health care system is publicly funded and health care services are free of charge to the individual. This study was approved by the Danish Data Protection Agency (J.nr.2013-41-2323) in accordance with Danish law.
Data sources
Patients were identified in The Danish Database for Hepatitis B and C (DANHEP).
DANHEP is a nationwide database with on-going enrolment since 1 January 2002 [16] .
Briefly, it contains demographic, clinical, Transient Elastography (TE) measurements, liver biopsy, and laboratory data on patients seen at least once in a specialized outpatient clinic with CHC and/or chronic hepatitis B (CHB). All patients give oral and written consent to be registered in DANHEP. Cross-linkage between nationwide registries is possible due the unique ten-digit Personal Identification Number (PIN) [15] given to all residents in Denmark and registered in the The Danish Civil Registration System, along with date of birth and death, e-and immigration-status, address etc.. All hospital admission dates and diagnoses are registered in The Danish National Patient Registry (NPR) [17] , histopathologic diagnoses in The National Danish Pathology Database (Patobank) [18, 19] , and cancer diagnoses in The Danish Cancer Registry [13] . For further details on the registries see supplementary material.
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Cohort selection
Patients registered in DANHEP were included if they fulfilled the following criteria: liver fibrosis assessment and enrolment in DANHEP before 31 December 2012, ≥ one positive HCV-RNA, ≥ 18 years of age, a valid PIN and address in Denmark. All ICD-and Snomed [20] codes used in the definitions of in-and exclusion criteria and covariates are provided in the supplementary data. To avoid reverse causation follow-up commenced six months after the first liver fibrosis assessment date or enrolment date in DANHEP , whichever occurred last, or 1 January 2002, from here on referred to as baseline. Liver fibrosis assessment was based on the following methods: liver biopsy assessed by Metavir fibrosis score (F0 -F4) [21] , TE (Fibroscan®, Echosens, Paris, France) median elasticity [22] with ≥ 10 valid measurements and an interquartile range ≤ 30% of the median elasticity [23] , clinical cirrhosis (ascites, hepatic encephalopathy (HE), oesophageal varices, oesophageal variceal haemorrhage, spontaneous bacterial peritonitis). Cirrhosis was defined as the presence of one of the following: liver biopsy (F4), TE median elasticity ≥ 17.0 kPa [24] , or clinical cirrhosis. The cut-off of 17.0 kPa was based on a prospective study reporting similar rates of liver-related complications among CHC patients with a median TE ≥ 17.0 kPa and patients with biopsy confirmed cirrhosis [24] . Patients who did not fulfil the cirrhosis-criteria were classified as non-cirrhotic. For patients enrolled without cirrhosis who subsequently developed cirrhosis, the cirrhosis baseline was defined as the first date of cirrhosis, and they contributed with risk time as both non-cirrhotic and cirrhotic. 
Outcome and covariates
Patients and comparison individuals were followed from baseline until the primary outcome death from any cause, loss to follow-up, or 31 December 2013, whichever occurred first. Psychiatric disease was defined as a diagnosis of psychiatric disease registered in NPR.
SVR24 was registered in DANHEP and was defined as the absence of HCV-RNA 24 weeks after EOT. Non-SVR24 was defined as a treatment with known treatment response that did not result in SVR24. The date 24 weeks (168 days) after EOT is referred to as the EOT24 date. Reinfection was defined as at least one positive HCV-RNA after a period with undetectable HCV-RNA after the EOT24 date.
Statistical analysis
For comparison of baseline characteristics the Mann-Whitney U test or Chi-square test was applied for statistical significance. The CCI score did not show log linearity and thus was kept as close to the original scale, while ensuring events in all strata, by creating a categorical covariate with levels from 0 to ≥ 6. In the analyses including only patients, age, psychiatric disease, CCI score, cirrhosis, LTX, liver decompensation, antiviral treatment, and HCC were always introduced as time-A c c e p t e d M a n u s c r i p t 9 dependent covariates with the aforementioned strata, whereas sex, alcohol overuse and IDU were introduced as categorical covariates. Alcohol overuse and IDU were used as categorical baseline covariates due to the causal link between IDU and CHC and between alcohol overuse and cirrhosis. The MRR associated with cirrhosis among CHC patients was adjusted for alcohol overuse, IDU, sex, psychiatric disease, age, and CCI score.
Using different models we calculated MRR adjusted for relevant confounders associated with initiating antiviral treatment, LTX, HCC, IDU, alcohol overuse and liver decompensation among CHC patients with cirrhosis. Mortality associated with SVR24 in cirrhotic patients who reached at least one EOT24 date before the end of follow-up was adjusted for sex, IDU, alcohol overuse, psychiatric disease, liver decompensation, HCC, LTX, age, and CCI score. In this analysis, time to event was time from the first EOT24 date or the cirrhosis baseline, whichever occurred last, until end of follow-up. We included figure 3 (log-rank test p < 0.0001).
DISCUSSION
We found a markedly increased mortality in CHC patients with cirrhosis compared to both non-cirrhotic CHC patients and the general population and were able to demonstrate reduced mortality associated with achieving SVR24 among CHC patients with cirrhosis, although mortality remained high compared to the general population. To our knowledge this is the first time a large cohort of CHC patients with cirrhosis, enrolled from all specialized departments in a country, has been characterized and compared to a cohort of non-cirrhotic CHC patients and the general population taking important confounders into account in a time-dependent manner.
In our cohort the adjusted MRR observed between patients without cirrhosis and comparison individuals (table 3) , were generally lower than those reported by Omland et al. [11] and generally higher for patients with cirrhosis. This is not surprising since the A c c e p t e d M a n u s c r i p t 13 cohort in the Danish study by Omland et al. included almost all patients with CHC but did not include information about cirrhosis. It is, however, important to consider the fact that the mortality in our cohort of patients without cirrhosis was artificially low because deaths occurring after a diagnosis of cirrhosis were censored from the cohort of patients without cirrhosis. The average annual mortality of around 4% and standardized mortality rate ratios between 3 and 4 described in studies [4, 5, 33, 34] including CHC patients with almost exclusively compensated cirrhosis are lower than the mortality described in this study. This was despite of slightly older cohorts [4, 5] , higher prevalence of Diabetes Mellitus [32] and the inclusion of 7% patients with competing causes of liver diseases [4] . However, these studies are likely to have included highly selected cohorts of patients included from a single or few centres involving few patients with IDU, few patients with moderate to high alcohol intake (≥ 40 grams/day) and only including patients willing to attend regular visits [4] or be enrolled in a clinical trial [32] . How much of the increased mortality in patients with cirrhosis seen in our cohort compared to the general population is caused by CHC, cirrhosis, IDU and alcohol overuse, or unaccounted for confounding, cannot be determined based on the data in this current study. However, the four-fold increase in mortality associated with cirrhosis among CHC patients can be seen as an estimate for the excess mortality in the presence of cirrhosis.
Van der Meer et al. demonstrated a reduced mortality associated with achieving SVR24 in CHC patients with advanced hepatic fibrosis [10] . We confirmed a reduction in all-cause mortality associated with SVR24 in a large cohort of CHC patients with cirrhosis. The reduction in mortality associated with initiation of antiviral treatment is probably the result of a selection effect more than a survival benefit per se given the many contraindications to interferon-based regimes [33, 34] . With the introduction of direct-acting antivirals with A c c e p t e d M a n u s c r i p t 14 very few contraindications, even patients with advanced liver disease are eligible for treatment and can achieve high SVR rates [35, 36] . Henceforth the biological effect of eradicating HCV will expectedly become even more pronounced in future research.
However, active alcohol abuse and IDU remain relative contraindications to treatment with direct-acting antivirals [37] . In our cohort, current or past alcohol overuse was prevalent, more frequent in cirrhotic patients and associated with increased mortality. This is not surprising since alcohol abuse increases the risk of developing cirrhosis in CHC patients [38, 39] . In contrast current or past IDU was not associated with increased mortality. This probably reflects that ongoing IDU was low in this population.
In contrast to previous studies [40, 41] we found that despite SVR24 CHC patients with cirrhosis showed a mortality rate two-fold that of the general population. In one study [40] follow-up commenced at the start of antiviral treatment and it is unclear whether immortal time-bias was present in the comparison with the general population. Another possible explanation for the higher mortality found after SVR24 may be that patients included in our study had higher prevalence of alcohol overuse, comorbidity and more advanced liver disease (supplementary table 1). Although the follow-up in our study was shorter, the comparison cohort from the general population was more precisely matched, and we could adjust for important confounders in a time-dependent manner. Although achieving SVR24 no doubt decreases mortality in patients with cirrhosis, in many settings, however, mortality rates comparable to that of age-and sex-matched peers free of CHC and cirrhosis does not necessarily follow. This may be the result of risk factors present in the CHC patient population such as substance abuse and comorbidities.
Among the strengths of this study is the setting with prospectively collected data on all CHC patients seen in outpatient clinics in Denmark. The unique PIN with the option to link A c c e p t e d M a n u s c r i p t 15 between various national registries ensures negligible loss to follow-up. Changing the TE cut-off for cirrhosis to ≥ 13.01 kPa [42] identified an additional 70 patients with cirrhosis but did not change the results significantly (data not shown). This real world study had minimal selection bias among patients attending specialized care but unfortunately did not cover the majority of patients with diagnosed and undiagnosed CHC in Denmark [2] , which limits the generalizability of the results. The fact that 25% of patients had cirrhosis at baseline suggests that our population is a skewed population with regards to liver disease [1] . Other limitations include the fact that we had no information on smoking, HCV-RNA concentrations, CHC duration, Child-Pugh classification, body mass index, quantity of alcohol use, and whether IDU or alcohol overuse were current or past. This limited our ability to properly adjust for risk factors associated with CHC compared to the general population. The incidence rate of cirrhosis in this study was based on a relatively short follow-up time and thus cannot be used to draw any conclusions on the long-term natural history of CHC infection.
In conclusion, mortality was substantially increased among patients with CHC and cirrhosis seen in Danish outpatient clinics compared to CHC patients without cirrhosis and the general population. Cirrhosis in CHC patients was associated with a four-fold increase in mortality and SVR24 was associated with reduced mortality in patients with cirrhosis.
However, even after SVR24, mortality remained elevated compared to the general population, and a history of alcohol overuse or IDU, comorbidities and psychiatric disease were prevalent and are important health issues that need to be addressed. 
